Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling about 1.5%.
The iShares Biotechnology ETF (IBB) dropped 2.6%.
In corporate news, Guardant Health (GH) was up about 16% after the Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for its Shield blood test for colorectal cancer screening.
Quanterix (QTRX) shareholder Kent Lake said it opposed the firm's proposed deal with Akoya Biosciences (AKYA). Quanterix was up 2%, and Akoya gained 3.3%.
Arvinas (ARVN) and Pfizer (PFE) said a phase 3 trial of vepdegestrant to treat advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but didn't reach statistical significance in progression-free survival improvement in the intent-to-treat population. Arvinas tumbled 51%, and Pfizer was down 2.5%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。